RETRACTED: Rheumatoid arthritis (RA) and cardiovascular disease
Publication date: Available online 1 August 2020Source: Autoimmunity ReviewsAuthor(s): Arnon Blum, Mohammad Adawi
Authors: Khazzam M, Gee AO, Pearl M Abstract The Management of Glenohumeral Joint Osteoarthritis Evidence-Based Clinical Practice Guideline is based on a systematic review of published studies for the treatment of glenohumeral joint osteoarthritis. The purpose of this clinical practice guideline is to address the management of patients with glenohumeral joint osteoarthritis. It is not intended to address the management of glenohumeral joint arthritis from etiologies other than osteoarthritis (ie, rheumatoid arthritis, inflammatory arthritis, posttraumatic arthritis, osteonecrosis, rotator cuff tear arthroplasty, ca...
CONCLUSIONS: . Although ADR data in the DREAM-RA registry were partly comparable with data in the SmPCs, RWD from this patient registry provided an added value to the currently available information on the incidences of ADRs associated with DMARDs in RA patients as described in SmPCs. PMID: 32990050 [PubMed - as supplied by publisher]
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...
Conditions: Rheumatoid Arthritis; Exercise; Exercise Therapy Interventions: Other: Aerobic Exercises; Other: Resistive Exercises; Other: Range of Motion Exercises Sponsor: Sisli Hamidiye Etfal Training and Research Hospital Recruiting
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.0c13261
Contributors : Vinod Krishna ; Sunil NagpalSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe study a new pathogenic, glycolytic PD1+ B cell population in sites of inflammation of patients with Rheumatoid Arthritis (RA).
Nature Reviews Rheumatology, Published online: 30 September 2020; doi:10.1038/s41584-020-00521-xCardiac toxicity can be induced by hydroxychloroquine, especially when used in combination with azithromycin. Interest in hydroxychloroquine and azithromycin as potential therapies for COVID-19 has renewed concerns about the possible cardiovascular risk these drugs present to patients with rheumatoid arthritis.
ConclusionMedical management of patients with RA has reduced the need for THA, while postoperative medical and surgical management has improved some postoperative outcomes. Nevertheless, there remains room for further improvement to postoperative outcomes through RA-specific management.
Tenascin-C (TNC) is a large multimodular glycoprotein of the extracellular matrix that consists of four distinct domains. Emerging evidence suggests that TNC may be involved in the pathogenesis of osteoarthritis (OA) and rheumatoid arthritis (RA). In this review, we summarize the current understanding of the role of TNC in cartilage and in synovial biology, across both OA and RA. TNC is expressed in association with the development of articular cartilage; the expression decreases during maturation of chondrocytes and disappears almost completely in adult articular cartilage. TNC expression is increased in diseased cartilag...